A drug development program targeting vocal fold scarring, aimed at obtaining proof of concept (POC) through a placebo-controlled, double-blind next-phase trial and a Phase III trial conducted based on consultations with the PMDA. The program covers advancing clinical development, including expanding the number of clinical trial sites.